This longitudinal single-center study describes the timing and risk factors for genital human papillomavirus (HPV) disease in women after allogeneic hematopoietic cell transplantation (HCT). Between 1994 and 2014, 109 females underwent HCT of whom 82 surviving transplant for 41 year had regular, comprehensive genital tract assessment and treatment of HPV disease. The cumulative proportions of any genital HPV infection at 1, 3, 5, 10 and 20 years were 4.8%, 14.9%, 28.1%, 36.7% and 40.9%, respectively. Demographic, disease-related factors, chronic GvHD (cGvHD) and its treatment were analyzed for their association with persistent, multifocal or severe genital HPV disease. Pre-transplant HPV disease was strongly associated with any posttransplant HPV (odds ratio (OR) = 6.5, 95% confidence interval (CI) = 1.65-25.85, P = 0.008). Having either extensive or genital cGvHD was associated with increased risk of any HPV disease (OR = 5.7, 95% CI = 1.90-17.16, P = 0.002) and a higher risk for severe genital dysplasia (CIN II-III/VIN II-III; OR = 13.1, 95% CI = 1.59-108.26, P = 0.017), but no one developed HPV-related genital cancer. Persistent, multifocal or severe HPV disease occurred more frequently than in healthy populations. Women with extensive cGvHD, genital cGvHD or pre-transplant HPV are at greatest risk for post-transplant HPV disease. Early initiation of annual screening, comprehensive genital tract assessment and active management are cornerstones of their gynecology care. 
INTRODUCTION
Human papillomavirus (HPV) has an estimated overall prevalence of 27% in women aged 14-59 years. 1, 2 Found in 20% of teenagers, the prevalence then increases to 45% in women aged 20-24 years and slowly declines to a plateau of 5% in women over age 50 years. 2 Of over 200 HPV types, more than 40 infect the genital tract and other mucosa, leading to papilloma formation. 3 Fourteen high-risk types most commonly affecting the cervix, anus or nasopharynx, account for 5% of all cancers worldwide. 4 ,5 Almost all cervical cancers and an estimated 60-80% of vulvar and vaginal cancers arise from HPV infection. 6 In healthy women, initial HPV epithelial changes may develop into invasive cervical cancer over a period of 10 to 30 years, 7 with persistent active high-risk HPV infection being the largest risk factor. 8, 9 Many infections initially clear and become undetectable only to develop cervical changes or active HPV later in life, suggesting the virus may be latent for years. 10 Identification and treatment of high-grade lesions decreases the risk of progression to cancer. As most HPV infections are asymptomatic, current screening includes cervical cytology and HPV DNA testing, which assess cellular changes and viral presence, respectively.
Survivors of hematopoietic cell transplant (HCT) are vulnerable to HPV reactivation, due to immune dysregulation and loss of HPV seroreactivity, and cervical HPV infection is found in a third of female long-term survivors. 11 Subsequent neoplasms are a potentially lethal late complication occurring in 2-12% of HCT survivors. [12] [13] [14] Squamous cell cancers, the commonest posttransplant solid tumors, are associated with HPV infection. 15 Cervical carcinoma in situ, the third most common solid tumor in one study, 13 posed a 13-fold increased risk of cervical cancer compared with the general population 15 and conferred a significant mortality risk. 16 Chronic GvHD (cGvHD) and its treatment has been strongly correlated to the increased risk of squamous cell carcinomas in the oral cavity, skin and other locations. 17 Previous studies of HPV in HCT survivors are limited by their focus on cervical dysplasia alone and their cross-sectional design. Our prior studies have associated the occurrence of cervical dysplasia with extensive cGvHD and use of immunosuppression at 3 years post transplant. 11 Wang et al. 18 found high-grade cervical cytologic abnormalities in almost a quarter of women who had no history of pre-transplant abnormal cytology and identified vulvovaginal (genital) cGvHD as a significant risk factor. In considering the long-term risk of HPV reactivation, factors related to HPV such as a history of pre-transplant abnormal cytology, dysplasia or genital warts, time to HPV disease, occurrence of 1 severe or persistent HPV and HPV involving more than one genital location warrant study. This study aims to more clearly define the risk factors, extent, recurrence patterns and the time-course of genital HPV disease in these women which, in turn, may guide screening and treatment practices.
PATIENTS AND METHODS
This combined retrospective (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) and prospective (2005 onward) long-term study evaluated gynecologic history and assessment, cervical cytology and HPV testing in a cohort of female HCT survivors transplanted between 1994 and 2014 at the National Institutes of Health Clinical Center in Bethesda, MD, in one of several institutional review board-approved protocols. Institutional review board approval for this analysis is covered under protocols 05-H-0130, 12-H-0028, 13-H-0144 and 17-H-N-001. Patients had undergone HLA-identical sibling HCT, with six subjects receiving a non-myeloablative regimen with Fludarabine (total 125 mg/m 2 ) plus cyclophosphamide (total 120 mg/kg). The other subjects received a fully ablative or reduced intensity regimen with the addition of TBI 400-1360 cGy. Single-agent cyclosporine was used for GvHD prophylaxis. Subjects were included in the study if they had survived at least 1 year after transplant and underwent a gynecologic exam.
Baseline clinical information included age at transplantation, hematologic diagnosis, disease risk, stem cell source, conditioning therapy and smoking history. Gynecologic information included pre-transplant gravida and parity, marital status, sexual activity, menopause, hormone replacement therapy, as well as any history of abnormal pap, genital warts, HPVrelated genital dysplasia and gynecologic surgery for any indication. Patients were followed prospectively for relapse, cGvHD including genital cGvHD and use of immunosuppressive therapy (IST) at 43 years or not. cGvHD was classified as extensive or limited. 19 After 2005, female patients over age 18 years underwent gynecologic assessment pretransplant and annually under the direction of a senior gynecologist (PS). Women were seen more frequently if they had any gynecologic complaints. At each visit, a detailed gynecologic history was obtained as well as screening for genital cGvHD. Cervical cytology and HPV testing were performed annually in keeping with current ASBMT guidelines. 20, 21 Cytological abnormalities were classified according to the Bethesda 2001 classification system: atypical squamous cells of undetermined significance, atypical glandular cells of undetermined significance, low-grade squamous intraepithelial lesion, or high-grade squamous intraepithelial lesion. 22 Patients with abnormal cervical cytology defined as atypical squamous cells of undetermined significance with positive HPV (high or low risk types) or worse underwent colposcopic evaluation. The vagina and vulva were also inspected and visible lesions were biopsied. Patients with biopsies showing only HPV changes or CIN I underwent repeat cytology in 1 year. A strategy to limit risk of progression to HPV-related cancer was adopted. Those with moderate dysplasia (CIN II) or greater, or with mild cervical dysplasia persisting for more than 3 years had an excisional procedure, most commonly a cold knife cone biopsy. Vulvar or vaginal lesions were biopsied and extensive HPV disease or severe dysplasia was treated with topical medication, laser ablation or excision. If a patient had testing or treatment outside of our institution, these records were obtained and reviewed.
Study outcomes included the occurrence and timing of 'any HPV', the severity of dysplasia, the extent of HPV lesions and the persistence of HPV disease. 'Any HPV', included abnormal cytology with positive HPV testing (high or low risk types) or visible HPV lesions. Mild dysplasia included condyloma and biopsy-proven cervical, vaginal or vulvar intraepithelial neoplasia grade I. Severe dysplasia included any biopsy-proven cervical, vaginal or vulvar intraepithelial neoplasia grade II or greater. Multifocal disease affected two or more genital locations (cervix and vulva for example), and persistent disease was defined as lasting more than 3 consecutive years. Each woman's course over time was reviewed individually and discussed between gynecologists (DS and PS) to confirm correct classifications.
Demographic, clinical and transplant characteristics were used to evaluate risk factors for HPV disease. Continuous variables included the following: age at transplantation, duration of follow-up and time to severe dysplasia, multifocal disease or persistent HPV. Other variables included disease risk: standard versus high (standard risk included patients in first complete remission with ALL and AML, and those with chronic phase CML); marital status; ethnicity; posttransplant relapse: yes versus no; acute GvHD (grade II-IV): present versus absent; cGvHD: limited versus extensive; IST: at Genital HPV in stem cell transplant survivors D Shanis et al 43years or not; genital cGvHD: present versus absent. As we began following women annually in 2005 and not all women had annual followup at our institution, the time to first cytology test after transplant was considered with regard to development of genital HPV disease. In univariate analyses, χ 2 -or Fisher's exact tests were used for categorical variables and the Mann-Whitney U-test for continuous variables. Logistic regression with backward stepwise variable selection was performed for the occurrence of any HPV post transplant, severe dysplasia, persistent disease or multifocal extent using SPSS v19 (IBM, Armonk, NY, USA). Statistical significance was accepted at Po 0.05.
RESULTS
One hundred and nine female patients underwent HLA-identical sibling HCT from 1994 to 2014. Patients who died within the first year after transplant (n = 11) and 16 others who did not undergo a gynecologic exam were excluded (Figure 1 ). Eighty-two women met the inclusion criteria. The median duration of follow-up was 5.2 years (Table 1 , range 0.3-17.4) with 93% undergoing myeloablative ex vivo T-lymphocyte-depleted cell transplantation with TBI. Fifty-six (68%) women developed cGvHD (25 limited, 31 extensive); 21 (26%) were diagnosed with genital cGvHD.
Fifteen (18%) women reported having an abnormal pap, dysplasia or genital warts before HCT. Seven (9%) patients underwent hysterectomy before transplant for fibroids (two), endometrial cancer that involved the cervix (Stage 2 endometrial, one), borderline ovarian tumor (one), grade 3 pap (one) and unknown (two). Four women had a hysterectomy after transplant for high-grade cervical and vaginal dysplasia (one), a pelvic malignancy (one) and fibroids (two). No one developed cervical or vulvar cancer. After transplant, all women with abnormal cytology were HPV positive, except for four women with low-grade squamous intraepithelial lesion who were HPV negative. Three had only low-risk HPV types paired with normal, atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion cytology (one each; Table 2 ).
Twenty-nine (35%) women had either an abnormal pap (n = 23) or genital HPV (n = 6) post transplant. Nearly half of these, 14 (17%) developed severe dysplasia, multifocal or persistent HPV disease requiring treatment (Table 3) . Three women had disease requiring multiple treatments. Eleven (13%) women had persistent HPV disease. There was no effect of age at transplantation, diagnosis, conditioning treatment, acute GvHD, ethnicity or time to gynecology visit after transplant on HPV disease. Of 24 women with available cytology and HPV testing at the time of relapse, 7 (30%) had HPV. Women who had a hysterectomy were more likely to have a history of pre-transplant HPV (Fisher exact test likelihood ratio = 4.3, P = 0.038) and multifocal HPV (likelihood ratio = 6.5, P = 0.014). Women who developed extensive cGvHD or genital cGvHD were more likely to undergo any gynecologic surgery after transplant (likelihood ratio = 9.4, P = 0.002).
The Kaplan-Meier cumulative incidence rates of any genital HPV infection at 1, 3, 5, 10 and 20 years were 4.8%, 14.9%, 28.1%, 36.7% and 40.1%, respectively (Figure 2a) . Women who developed extensive or genital cGvHD had a cumulative HPV rate of 67.1% versus 18.4% in women without (P = 0.001; Figure 2b ). The cumulative rate of severe dysplasia reached 19% at 20 years (Figure 3a) , a rate significantly different between women with and without extensive or genital cGvHD (41.2 versus 2.5%, P = 0.004, e Persistent disease lasting more than 3 consecutive years.
Genital HPV in stem cell transplant survivors D Shanis et al Figure 3b ). Of seven patients whose cytology testing was delayed until at least five years post transplant and who developed HPV disease, three had previously negative cytology testing, suggesting HPV reactivation. Of these three women, two had recently relapsed and received chemotherapy. The relationship between HPV disease and clinical factors in multivariate analysis are shown in Table 4 . Having had either genital or extensive cGvHD exerted the strongest impact on posttransplant HPV. It was significantly associated with the occurrence of any HPV disease (odds ratio (OR) = 5.7, 95% confidence interval (CI): 1.9-17.1, P = 0.002) as well as being the only variable associated with developing severe genital HPVrelated dysplasia (OR = 13.1, 95% CI: 1.6-108.3, P = 0.017). A history of pre-transplant HPV was significantly associated with the occurrence of any HPV disease (OR = 6.5, 95% CI: 1.6-25.9, P = 0.0008) and the only factor associated with having persistent or recurrent post-transplant HPV (OR = 23.2, 95% CI: 5.0-108.4, P o0.001). Hysterectomy either before or after transplantation was more likely to be associated with the occurrence of HPV in multiple lower genital tract sites (OR = 7.9, 95% CI: 1.6-37.8, P = 0.01).
DISCUSSION
With long-term follow-up, the cumulative incidence estimate of genital HPV infection approached 40% at 20 years in female HCT survivors. This is similar to previous reports of post-HCT cervical HPV/dysplasia ranging from 30 to 40%, which did not assess vaginal or vulvar disease. 11, 18 As women after transplant are infirm and frequently report impaired sexual function, 23 this high incidence of HPV infection likely reflects viral reactivation rather than newly acquired infection. For those with severe dysplasia, early diagnosis enabled early treatment and few women required multiple procedures. During our study period, no patients developed an HPV-related genital tract cancer.
The occurrence of HPV infection within the first few years post transplant strongly supports initiating annual gynecological screening as recommended in current transplant guidelines 20, 21 rather than every 3 years as recommended for healthy women. 24 Annual cytology testing is especially important in those with extensive or genital cGvHD, malignancy relapse or evidence of immunocompromise (from transplant or treatment). For those without these issues, it might be reasonable to consider lengthening screening intervals to every 2-3 years if normal cytology is observed in the first few years after transplant.
Whether viral reactivation is increased by cGvHD itself, IST, impaired immune function from transplant or a combination is unknown. Genital cGvHD 18 and IST (43 years) 11 are reported risk factors for HPV-related cervical dysplasia, cGvHD and its treatment are associated with other, likely HPV-related squamous cell cancers, 17 and genital cGvHD treated with topical immunosuppression is associated with HPV reactivation post transplant. 25 We used extensive cGvHD and genital cGvHD as a surrogate for prolonged immunosuppression as quantifying cumulative IST exposure is difficult and unreliable.
The immune response to an oncogenic virus such as HPV is both antibody and cell mediated. Clinical evidence suggests that a functional T-cell response is the major mechanism of immunity. 26 After transplant, lymphopenia and cell-mediated immune deficiency affects T-cells, natural killer cells and reduced antibody production for years. These immune impairments are exacerbated by cGvHD and associated IST. 20 Once the HPV virus is active, genetic factors, disease type, cGvHD, conditioning regimens and treatments may affect risk of progression to cancer, 14 a risk that may be mitigated by surveillance and treatment of severe or persistent dysplasia.
Compared with healthy populations with a reported incidence of 9, 1 and 7%, [27] [28] [29] our study found that persistent, multifocal or severe genital HPV disease occurred in 13-17% of women overall. Aldabagh et al. 26 also found that HPV disease is often multifocal in immunocompromised women, an important consideration as others have reported an increased risk of either vulvar cancer or cervical cancer post transplant. 30 In this study, women who underwent hysterectomy were at increased risk of multifocal HPV, illustrating the importance of assessing the vagina and vulva in all patients, even those who have undergone a hysterectomy.
HPV disease and genital cancer risk after HCT likely is deserving of a prospective study, yet such a study requires close collaboration between transplant teams and gynecologists over the long term. The close collaboration between the transplant and gynecology teams, the review of the longitudinal clinical course by two gynecologists (DS and PS) and the supervision of care by a single senior gynecologist (PS) expert in the health of female HCT survivors are significant strengths of this study. Our combined retrospective and prospective study is the most comprehensive to date and similar studies are not likely to be undertaken. Studies that rely on central reporting by transplant teams and interpretation of gynecologic events have significant limitations because of the risk of underreporting or misreporting. For example, some studies have included cervical carcinoma in situ as a cancer diagnosis when, in fact, carcinoma in situ is severe dysplasia, not cancer. 13 A limitation of the study is that it was not prospective for all subjects due to our international population who have screening and follow-up by physicians outside our institution and, at times, outside of the country likely resulting in an underestimation of multifocal HPV disease and genital cGvHD, as well as the rates of pre-and posttransplant HPV infection. Screening and treatment varied, and information on other HPV risk factors, such as smoking, were not consistently available. In addition, current methods for HPV screening detect genital infection pooled as either high or low risk types, but do not measure antibodies indicating past viral exposure. 31 In conclusion, in a cohort of female allogeneic HCT survivors with long-term, regular follow-up after transplant, HPV disease occurred in 40%, mostly within 5 years of transplant. No one developed genital HPV-related cancer to date. Given the increased risk of cervical and vulvar cancer in these patients, annual screening and aggressive management enables early identification and treatment of severe dysplasia or multifocal disease, limiting persistence and risk of progression to cancer. As this high rate of HPV likely reflects viral reactivation, our findings implicate a critical role for dysregulation of the immune system and the timing of reactivation suggests a window for vaccination. The occurrence of severe dysplasia, widespread genital HPV or persistent HPV and their respective association with extensive cGvHD or genital cGvHD, hysterectomy and history of pretransplant HPV in transplant survivors identifies those at greatest risk of developing HPV disease and emphasizes the importance of assessing the whole genital tract. As HPV disease can persist and progress, regular gynecologic follow-up would likely benefit women after transplant. Genital HPV in stem cell transplant survivors D Shanis et al
